Dr. Zhang is the Founder and CEO of OneTwenty Therapeutics, Inc., and CTO of Help Therapeutics Co’ Ltd., a clinical stage iPSC-based cell therapy company. He was the CEO of Hanhai Silicon Valley, Inc., an early-stage investor and cross-border incubator for life sciences and deep tech startups based in San Francisco Bay Area.

Prior to Hanhai, Alex was the Co-founder and Managing Partner of Enverest, LLC., a Silicon Valley based innovation solutions and investment advisory firm, with branch offices in China and Singapore. Prior to founding Enverest, Dr. Zhang spent over four years at Thermo Fisher Scientific, where he held several senior business roles. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Over the past decade, Dr. Zhang has been advising a number of successful biotech, MedTech and digital health startups and venture capital firms.

Dr. Zhang is currently a Board Member of the Chinese America BioPharmaceutical Society (CABS). He served a number of leadership roles in the Executive Council of CABS, including as the President in 2017-18. Dr. Zhang earned MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. His research has led to the publication of 17 peer reviewed articles and 4 patents.